Condition (MeSH)
Substance Abuse, Intravenous
ClinicalTrials.gov lists 32 trials for Substance Abuse, Intravenous or a narrower condition beneath it. National Institute of Allergy and Infectious Diseases (NIAID) has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
32 of the 32 trials are tagged with Substance Abuse, Intravenous itself; the rest are tagged with a narrower condition beneath it.
When did Substance Abuse, Intravenous trials start? (15)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2023 | 2 |
| 2021 | 3 |
| 2020 | 1 |
| 2017 | 2 |
| 2016 | 5 |
| 2015 | 4 |
| 2012 | 1 |
| 2011 | 1 |
| 2009 | 2 |
| 2006 | 1 |
Showing 10 of 15 earlier years.
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 32 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Substance Abuse, Intravenous trials in? (6)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 3 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |
| Phase 4 | 5 |
| Not applicable | 12 |
| Observational | 7 |
How many Substance Abuse, Intravenous trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 1 |
| Active, not recruiting | 1 |
| Completed | 26 |
| Terminated | 1 |
| Withdrawn | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Substance Abuse, Intravenous trials? (4)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | 2 |
| Indivior Inc. | 1 |
| Merck Sharp & Dohme LLC | 1 |
| New River Pharmaceuticals | 1 |
Which drugs are being tested for Substance Abuse, Intravenous? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Buprenorphine | 3 |
| AIC (Amb a 1 Immunostimulatory Conjugate) | 1 |
| Dalbavancin | 1 |
| Peginterferon Alfa-2B | 1 |
| Lisdexamfetamine Dimesylate | 1 |
Interventions as named in the registry (9)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Oxygen (15-O) Water | 1 |
| MN rgp120/HIV-1 and A244 rgp120/HIV-1 | 1 |
| Hepatitis A & B vaccine | 1 |
| Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP) | 1 |
| Elbasvir/Grazoprevir | 1 |
Showing 5 of 9 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Substance Abuse, Intravenous trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Death | 9 | 1 |
| Hospitalization for general medical treatment | 2 | 1 |
| Convulsion | 1 | 1 |
| Death from heart attack | 1 | 1 |
| Diabetes mellitus | 1 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Substance Abuse, Intravenous? (613)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| A Mobile Health Application to Support Reductions in Overdose Risk Behaviors: A Pilot Study. | Substance use & addiction journal | 2026 | Yes |
| A Dyad-Based Intervention to Improve Adherence to Antiretroviral Therapy among People with HIV who Inject Drugs in Kazakhstan: Results of a Randomized Controlled Trial. | AIDS and behavior | 2026 | Yes |
| Integration of safer smoking equipment in U.S. syringe services programs: Qualitative insights from program staff. | The International journal on drug policy | 2026 | Yes |
| Mobile Telemedicine for Treating Chronic Hepatitis C Among Rural People Who Inject Drugs: A Randomized Clinical Trial. | JAMA network open | 2026 | Yes |
| Estimating hepatitis C prevalence in the United States, 2017-2020. | Hepatology (Baltimore, Md.) | 2025 | Yes |
Showing 5 of 613 publications.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.